Marketing: Page 51
-
Can too many safety warnings overwhelm consumers?
Two FDA experiments will test whether repetition of safety warnings in DTC ads negatively affects consumers’ attention to drug risks.
By Barbara Boughton • June 21, 2017 -
Shire's ADHD drug secures FDA OK
The Irish pharma expects to start commercializing Mydayis in the third quarter.
By Jacob Bell • June 21, 2017 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineCommercialization
New drugs for obesity are becoming blockbusters, while Trump administration pressure is reshaping pharma marketing strategies ahead of looming patent cliffs.
By BioPharma Dive staff -
Deep Dive
FDA targets regulatory 'gaming' to boost generic competition
While the FDA has no direct role in drug pricing, agency head Scott Gottlieb hopes his planned actions could help address rising costs — at least in part.
By Ned Pagliarulo • June 21, 2017 -
Pricing pressures lower drug sales forecasts, new report finds
It was the first lowering of long-term sales expectations in the 10-year history of EvaluatePharma's World Preview reports.
By Jacob Bell • June 21, 2017 -
Humira shows its staying power
Pfizer had hoped head-to-head data comparing its JAK inhibitor Xeljanz to Humira would help steal market share, but the newer drug showed mixed results.
By Suzanne Elvidge • June 19, 2017 -
EpiPen alternative Symjepi gets FDA OK
Adamis Pharmaceuticals plans to launch its allergic reaction drug later this year.
By Jacob Bell • June 16, 2017 -
Pfizer, Roche, Aspen under investigation for cancer drug pricing
South African's Competition Commission is looking into the "excessive pricing" of Herceptin, Xalkori and a few generic medications.
By Jacob Bell • June 14, 2017 -
Rebates not to blame for rising drug costs, says PBM trade group
A new report from PCMA found no correlation between rebate levels and increasing prescription drug costs among the top 200 brands.
By Ned Pagliarulo • June 14, 2017 -
Report: Pharma spend helps push medical costs up
New research from PwC expects inflation, a lack of generic drugs and a more tepid response to high-deductible insurance plans are likely to increase medical costs next year.
By Jacob Bell • June 14, 2017 -
Sponsored by ZS AssociatesHow biopharma companies can adapt to industry changes
Commercial organizations in the biopharma industry need to move away from generalist roles into more specialized roles.
By Jude Konzelmann and Karan Dhundia • June 13, 2017 -
Deep Dive
Alternative pricing models a fantasy for gene therapies?
With an approval of Spark Therapeutics' gene therapy for a rare eye disease rapidly approaching, new questions about pricing are being raised.
By Lisa LaMotta • June 12, 2017 -
Deep Dive
5 Trends affecting gene therapy development
A pricing conundrum and ethical decisions are clouding an already hazy path to market for many gene therapy drugs and providers.
By Jacob Bell • June 12, 2017 -
Lilly preps galcanezumab for 2017 filing
The migraine drug showed strong efficacy across a trio of late-stage studies, and its submission to the FDA should come later this year.
By Jacob Bell • June 10, 2017 -
Strokes on the rise, but NOACs not filling the gap
New oral anticoagulants have become the new standard of care for stroke treatment, but the drugs have not lived up to expectation.
By Barbara Boughton • June 9, 2017 -
ADA preview: 5 things to watch in diabetes
Cardiovascular outcomes data, insulin pricing and technology are just a few of the things acting as major change agents in diabetes.
By Lisa LaMotta • June 9, 2017 -
AMA to vote on resolution calling for inclusion of drug prices in DTC ads
The American Medical Association has been outspoken on DTC advertising before, calling for a ban in 2015 on such marketing for pharmaceutical products.
By Barbara Boughton • June 7, 2017 -
Remodeled drug pricing bill likely to get Nevada Gov.'s signature
The new legislation requires drug manufacturers and PBMs to provide information to the state about price hikes for essential diabetes medicines.
By Jacob Bell • June 7, 2017 -
AbbVie, Novo, Takeda have best reputations in pharma, new study finds
Perceptions were mostly positive about the industry's commitment to financials and effective products, but not as much when it came to ethics.
By Jacob Bell • June 2, 2017 -
Opinion
The perils of building clinical trials on a shaky foundation
With the odds stacked against clinical trial success, drug developers need all the tools in their arsenal to make sure they recruit patients quickly and design trials effectively.
By Craig Morgan • June 1, 2017 -
Report: Oncology costs increasing faster than before
A QuintilesIMS study highlights the increased efficiency of the regulatory process for cancer drugs, a welcome development but one that has buoyed spending.
By Lisa LaMotta • June 1, 2017 -
US may have overpaid $1.3B for Mylan's EpiPen, HHS watchdog says
Mylan has yet to finalize a settlement with the DOJ to resolve allegations it misclassified EpiPen as generic and therefore paid lower rebates.
By Ned Pagliarulo • June 1, 2017 -
Lilly's Strattera faces first wave of generic competition
The FDA approved copycat versions of the big drugmaker's ADHD medication on Tuesday, which should cause a sizable hit to its 2017 revenues.
By Jacob Bell • May 31, 2017 -
Novartis' Zykadia gets 1st-line nod in ALK+ lung cancer
The expanded approval cements Novartis’ position in the market for treatment of ALK-positive NSCLC patients.
By Barbara Boughton • May 31, 2017 -
Drug rebates may shift costs to Medicare, study finds
While industry argues rebates lower drug and premium costs, a new paper suggests the practice leads to higher out-of-pocket spending and a heavier burden on Medicare.
By Ned Pagliarulo • May 31, 2017 -
AstraZeneca taps outcomes deals to boost CV, diabetes meds
Two agreements with Harvard Pilgrim for Brilinta and Bydureon will link drug cost to certain patient outcomes — the most recent examples of value-based deals.
By Ned Pagliarulo • May 31, 2017
Previous
